202220212020201920182017201620152014 January 19, 2022 Summary ToggleSpero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients January 04, 2022 Summary ToggleSpero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720 January 03, 2022 Summary ToggleSpero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis November 17, 2021 Summary ToggleSpero Therapeutics to Present at Upcoming Investor Conferences November 10, 2021 Summary ToggleSpero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update November 03, 2021 Summary ToggleSpero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021 October 28, 2021 Summary ToggleSpero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis October 12, 2021 Summary ToggleSpero Therapeutics Appoints Kathleen Tregoning to its Board of Directors October 01, 2021 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 30, 2021 Summary ToggleSpero Therapeutics Enters Into a Non-Dilutive Revenue Interest Financing Agreement With HealthCare Royalty Partners® for Up to $125 Million Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
